Beta Bionics Inc. logo

Beta Bionics Inc. (BBNX)

Market Closed
1 Sep, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
19. 07
-0.88
-4.411%
After Hours
$
20. 55
+1.48 +7.7609%
887.2M Market Cap
- P/E Ratio
- Div Yield
563,314 Volume
- Eps
$ 19.95
Previous Close
Add Transaction
Day Range
18.93 20.09
Year Range
8.8 32.71
Want to track BBNX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Beta Bionics, Inc. (BBNX) Q1 2025 Earnings Call Transcript

Beta Bionics, Inc. (BBNX) Q1 2025 Earnings Call Transcript

Beta Bionics, Inc. (NASDAQ:BBNX ) Q1 2025 Results Conference Call May 6, 2025 4:30 PM ET Company Participants Blake Beber - Head, IR Sean Saint - President and Chief Executive Officer Stephen Feider - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Mike Kratky - Leerink Partners Matthew Blackman - Stifel Travis Steed - Bank of America Jeffrey Cohen - Ladenburg Thalmann Brooks O'Neil - Lake Street Capital Markets Kelly Close - Close Concerns Operator Good afternoon, and welcome to the Beta Bionics First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Seekingalpha | 1 year ago
Beta Bionics: Slowing Down Or Being Conservative?

Beta Bionics: Slowing Down Or Being Conservative?

Beta Bionics' iLet product offers a simplified diabetes treatment, but shares have plunged 60% since the IPO due to a non-inspiring 2025 outlook, indicating potential lost market momentum. Despite strong initial growth and a significant IPO, the company's operating losses and competitive risks warrant a cautious investment stance. The 2025 sales guidance of $80-$85 million implies no sequential growth, raising concerns about market competitiveness and potential margin pressure.

Seekingalpha | 1 year ago
Insider Buying Surges in February, Especially in These 6 Stocks

Insider Buying Surges in February, Especially in These 6 Stocks

In January, the number of notable insider purchases was somewhat muted.

247wallst | 1 year ago
Beta Bionics: A Sugar Rush For This IPO

Beta Bionics: A Sugar Rush For This IPO

Beta Bionics' IPO was highly successful, trading 40% above the offer price due to strong growth prospects and relatively cheap sales multiples. The company's iLet product offers a new, simplified treatment for Type 1 diabetes, with plans to expand to Type 2, doubling the market potential. Despite impressive revenue growth, Beta Bionics faces substantial operating losses, but it has a solid cash position to fund these losses for years.

Seekingalpha | 1 year ago
U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipeline

U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipeline

Three very small Asian issuers and one blank check company listed in the US this past week, though the biggest headlines came from a sizable launch and notable new filings. Energy equipment and services provider Flowco launched the year's first major IPO, planning to raise $392 million and list in the week ahead. Two IPOs are currently scheduled in the week ahead, although some other small issuers may join the calendar throughout the week.

Seekingalpha | 1 year ago